ArticleBioMed research international2015
In vitro bactericidal activity of 4- and 5-chloro-2-hydroxy-N-[1-oxo-1-(phenylamino)alkan-2-yl]benzamides against MRSA.
Article in BioMed research international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Newly identified antimicrobial activity of an 8-hydroxyquinoline-based ionophore against multidrug-resistant Enterococcus faecium and Staphylococcus aureus.The Journal of antimicrobial chemotherapy · 2026Article
- Nanovesicle-Based Delivery of Magnesium Chlorophyllin for Photodynamic Inactivation in Agriculture.Small science · 2026Article
- In Vivo Study of Osseointegrable Bone Calcium Phosphate (CaP) Implants Coated with a Vanillin Derivative.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Antimicrobial and Antibiofilm Activity of Auranofin and Its Two Derivatives Bearing Naproxen and Acetylcysteine as Ligands Against Staphylococci.Antibiotics (Basel, Switzerland) · 2025Article
- Insight into antistaphylococcal effect of chlorinated 1-hydroxynaphthalene-2-carboxanilides.ADMET & DMPK · 2025Article
- Effect of novel antimicrobial blue light-emitting optical fiber on vancomycin-resistantJournal of bone and joint infection · 2025Article
- Antimicrobial and ADME properties of methoxylated, methylated and nitrated 2-hydroxynaphthalene-1 carboxanilides.ADMET & DMPK · 2025Article
- Antimicrobial effect of blue light on antibiotic-sensitive and drug-resistant Escherichia coli: a novel isotropic optical fibre.Access microbiology · 2025Article
- Design, Synthesis, and Anticancer and Antibacterial Activities of Quinoline-5-Sulfonamides.Molecules (Basel, Switzerland) · 2024Article
- Critical view on antimicrobial, antibiofilm and cytotoxic activities of quinazolin-4(3Heliyon · 2024Article
- A Potent and Narrow-Spectrum Antibacterial againstJournal of medicinal chemistry · 2023Article
- Titanium Dioxide Nano-Formulation: Characterization, Antimicrobial Activity, and Wound Healing in Animals.Animals : an open access journal from MDPI · 2023Article
- Enhancing Antifungal Treatment ofPharmaceuticals (Basel, Switzerland) · 2023Article
- Hydrocinnamic Acid and Perillyl Alcohol Potentiate the Action of Antibiotics againstAntibiotics (Basel, Switzerland) · 2023Article
- Trifluoromethylcinnamanilide Michael Acceptors for Treatment of Resistant Bacterial Infections.International journal of molecular sciences · 2022Article
- Design, Synthesis and Antimicrobial Properties of New Tetracyclic Quinobenzothiazine Derivatives.International journal of molecular sciences · 2022Article
- Comparison of In Vitro Approaches to Assess the Antibacterial Effects of Nanomaterials.Journal of functional biomaterials · 2022Article
- Study of Biological Activities and ADMET-Related Properties of Salicylanilide-Based Peptidomimetics.International journal of molecular sciences · 2022Article
- Zinc(II), Palladium(II), and Metal-Free Phthalocyanines Bearing Nipagin-Functionalized Substituents againstPharmaceutics · 2022Article
- Antistaphylococcal Activities and ADME-Related Properties of Chlorinated Arylcarbamoylnaphthalenylcarbamates.Pharmaceuticals (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A series of nine substituted 2-hydroxy-N-[1-oxo-1-(phenylamino)alkan-2-yl]benzamides was assessed as prospective bactericidal agents against three clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) and S. aureus ATCC 29213 as the reference and quality control strain. The minimum bactericidal concentration was determined by subculturing aliquots from MIC determination onto substance-free agar plates. The bactericidal kinetics of compounds 5-chloro-2-hydroxy-N-[(2S)-3-methyl-1-oxo-1-{[4-(trifluoromethyl)phenyl]amino}butan-2-yl]benzamide (1f), N-{(2S)-1-[(4-bromophenyl)amino]-3-methyl-1-oxobutan-2-yl}-4-chloro-2-hydroxybenzamide (1g), and 4-chloro-N-{(2S)-1-[(3,4-dichlorophenyl)amino]-3-methyl-1-oxobutan-2-yl}-2-hydroxybenzamide (1h) was established by time-kill assay with a final concentration of the compound equal to 1x, 2x, and 4x MIC; aliquots were removed at 0, 4, 6, 8, and 24 h time points. The most potent bactericidal agent was compound 1f exhibiting remarkable rapid concentration-dependent bactericidal effect even at 2x MIC at 4, 6, and 8 h (with a reduction in bacterial count ranging from 3.08 to 3.75 log10 CFU/mL) and at 4x MIC at 4, 6, 8, and 24 h (5.30 log10 CFU/mL reduction in bacterial count) after incubation against MRSA 63718. Reliable bactericidal effect against other strains was maintained at 4x MIC at 24 h.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.